You are here

Engineered T-cells show promise

Chimeric antigen receptor (CAR)-T-cells are a concept in development for treating cancer. Seattle researchers have published a new approach for developing CAR-T-cells. This new strategy could eventually lead to better outcomes for people living with HIV.

What is a CAR-T cell?

T-cell receptors help trigger immune responses. T-cell receptors are found on the surface of T cells, extending inside the cell to signal to other molecules. CAR-T cells have an engineered T-cell receptor. In a CAR-T-cell, the outer and inner segments of the receptor come from different molecules.

Why develop this approach for HIV?

Antiretroviral drugs don’t completely get rid of HIV infection. Natural immune responses are also not able to clear lingering virus. CAR-T-cells might be able to do what regular T cells can’t — kill HIV-infected cells remaining in the body during therapy. This is because CAR-T-cells recognise a broad range of HIV-infected cells, are potent and may be less affected by the blocks limiting regular T cells. CAR-T-cells have already been developed and tested in people living with HIV. Clinical trials of first-generation CAR-T-cells showed that the cells stay in the body for more than ten years, but do not reduce the amount of virus.

What’s different this time?

In the recent study, the outer segment of the T-cell receptor included parts of broadly neutralising antibodies (bNAbs) which effectively target multiple HIV strains. The researchers used an inner segment of the T-cell receptor from normal T cells, with co-stimulatory components that weren’t included in the first-gen CAR-T-cells. The researchers made the CAR-T-cells resistant to HIV infection by directing the T-cell receptor genes to the middle of the CCR5 gene. The engineered cells specifically targeted HIV-infected cells, and were resistant to HIV infection.

What exactly did the researchers do?

First, the researchers created CAR-T-cells from healthy human T cells using five different bNAbs. The researchers then tested the cells in a range of experiments. The CAR-T-cells became activated in the presence of HIV-infected cells, and could kill HIV-infected cells.

Secondly, the researchers selected the most potent CAR-T variant (PGT145-CAR) to test CCR5 disruption. Similar to the first lot of CAR-T-cells, the CCR5-edited CAR-T-cells were activated and could kill HIV-infected cells. In addition, the CCR5-edited CAR-T-cells were better at dealing with active virus replication.

What does this all mean?

This work shows the potential for engineered T-cells based on broadly neutralising antibodies that are themselves resistant to HIV infection.

These cells are specifically switched on when they encounter HIV antigens. They are able to kill HIV-infected cells even when there is a lot of HIV around because they don’t get infected and can maintain their potent function.

This work is still at an early stage. All of the experiments in this study were done in laboratory models of disease. The CCR5-edited CAR-T-cells haven’t been tested in humans yet. Recent funding announcements suggest that there is a lot of preclinical exploration of this promising strategy to come.

For the latest science visit HIV Cure

latest news

May 9, 2018
The federal government's budget details were released last night. Here's a community response.
March 29, 2018
We’re not talking about recovery parties here, but the post-recovery recovery when the festivities have ended.
March 21, 2018
The world has lost one of the most respected scientists in the field of HIV/AIDS, Professor David Cooper.
March 21, 2018
The cost of PrEP (pre-exposure prophylaxis) is to be drastically reduced from 1 April
February 12, 2018
The annual awareness day on 9 March is aimed at encouraging women to test for HIV.
January 22, 2018
Once again, 9 March commemorates the National Day of Women Living with HIV Australia. 
November 30, 2017
On a trip to Bali, David Menadue discovered that it pays to be clued up about travel insurance.
November 30, 2017
Armistead Maupin talks to Steven Petrow about 1970s San Francisco, AIDS and ageing.
November 30, 2017
This year marks the 30th anniversary of the AIDS Memorial Quilt. Read the story behind the icon.
November 29, 2017
They are the all-too forgotten minority: heterosexual men with HIV. Here are their stories.
November 29, 2017
In 2018, researchers will explore a number of approaches that might bring an end to the need for treatment.
November 29, 2017
As people with HIV get older and live longer, they become vulnerable to cardiovascular disease. 
August 22, 2017
A decision to subsidise PrEP has been deferred, much to the disappointment and frustration of HIV advocates.
July 26, 2017
Results from an Australian study show that HIV-positive men on treatment cannot transmit the virus.
June 22, 2017
Why is an easily curable disease once believed to be on the wane in Australia out of control?